| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C5aR1 |
| Uniprot No | P21730 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-350aa |
| 氨基酸序列 | MDSFNYTTPDYGHYDDKDTLDLNTPVDKTSNTLRVPDILALVIFAVVFLVGVLGNALVVWVTAFEAKRTINAIWFLNLAVADFLSCLALPILFTSIVQHHHWPFGGAACSILPSLILLNMYASILLLATISADRFLLVFKPIWCQNFRGAGLAWIACAVAWGLALLLTIPSFLYRVVREEYFPPKVLCGVDYSHDKRRERAVAIVRLVLGFLWPLLTLTICYTFILLRTWSRRATRSTKTLKVVVAVVASFFIFWLPYQVTGIMMSFLEPSSPTFLLLKKLDSLCVSFAYINCCINPIIYVVAGQGFQGRLRKSLPSLLRNVLTEESVVRESKSFTRSTVDTMAQKTQAV |
| 预测分子量 | 41.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C5aR1重组蛋白的3篇参考文献示例，涵盖结构解析、信号机制及疾病应用方向：
---
1. **文献名称**：**"Structural basis of C5a receptor-ligand binding reveals convergent activation mechanism"**
**作者**：Liu, H., Zhang, Y., & Kufareva, I. et al. (2021)
**摘要**：通过冷冻电镜解析人源C5aR1重组蛋白与配体C5a的复合物结构，揭示了受体激活的构象变化机制，为靶向C5aR1的药物设计提供结构基础。
2. **文献名称**：**"Targeted inhibition of C5aR1 with a novel monoclonal antibody attenuates inflammatory responses in sepsis models"**
**作者**：Guo, R.F., Riedemann, N.C., & Ward, P.A. (2017)
**摘要**：利用重组C5aR1蛋白筛选出特异性单克隆抗体，在败血症小鼠模型中验证其通过阻断C5a-C5aR1信号轴减轻过度炎症反应的作用。
3. **文献名称**：**"Recombinant C5a receptor expression system for high-throughput screening of allosteric modulators"**
**作者**：Bachelerie, F., Lagane, B., & Springael, J.Y. (2019)
**摘要**：开发基于HEK293细胞的重组C5aR1稳定表达系统，用于高通量筛选变构调节剂，为治疗炎症性疾病提供先导化合物。
---
**注**：以上文献信息为示例，实际引用时需核实具体发表信息及摘要内容。
C5aR1 (C5a receptor 1), also known as CD88. is a G protein-coupled receptor (GPCR) that plays a central role in the innate immune system by mediating responses to the complement activation fragment C5a. As part of the complement cascade, C5a is a potent anaphylatoxin generated during inflammation, infections, or tissue injury. C5aR1 is expressed on myeloid cells (e.g., neutrophils, macrophages) and non-myeloid cells (e.g., endothelial cells, neurons), where it regulates chemotaxis, cytokine release, and phagocytosis. Its signaling contributes to both protective immunity and pathological inflammation, making it a therapeutic target in diseases like sepsis, autoimmune disorders, and chronic inflammatory conditions.
Recombinant C5aR1 proteins are engineered versions of the receptor, typically produced in heterologous expression systems such as mammalian cells (e.g., CHO or HEK293) or insect cells. These systems enable post-translational modifications critical for receptor folding and ligand binding. The recombinant protein often includes tags (e.g., FLAG, His-tag) for purification and detection. Structural studies using recombinant C5aR1 have revealed its seven-transmembrane domain architecture and dynamic interactions with C5a, aiding in the design of antagonists to block excessive inflammation.
Research applications of recombinant C5aR1 include ligand-receptor interaction assays, high-throughput drug screening, and mechanistic studies of inflammatory pathways. Dysregulation of C5a-C5aR1 signaling is implicated in conditions like rheumatoid arthritis, Alzheimer’s disease, and COVID-19-related hyperinflammation, driving interest in developing biologics or small molecules targeting this receptor. Recent advances in cryo-EM and X-ray crystallography using recombinant C5aR1 have further elucidated its activation mechanisms, providing a framework for structure-based drug discovery.
×
